Evaluation of Hyperemia With the Use of Ocular Prostaglandin Analogues
NCT ID: NCT00539526
Last Updated: 2019-04-24
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
106 participants
INTERVENTIONAL
2007-09-30
2008-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Efficacy Study of Bimatoprost, Latanoprost, and Travoprost in Patients With Elevated Intraocular Pressure (IOP) and Open-angle Glaucoma (OAG)
NCT00716742
An Evaluation of Use of Topical Ocular Hypotensive Medication by Compliance
NCT00329095
Ocular Surface Tolerability Study of Prostaglandin Analogues in Patients With Open-Angle Glaucoma or Ocular Hypertension
NCT01253902
Influence of Prostaglandins on Ocular Blood Flow in Glaucoma Patients
NCT00308945
Safety and Efficacy of Bimatoprost Compared With Latanoprost in Patients With Glaucoma or Ocular Hypertension
NCT00541242
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
bimatoprost 0.03%
Bimatoprost 0.03%
bimatoprost 0.03%, 1 drop nightly for 3 months
2
travoprost 0.004%
travoprost 0.004%
travoprost 0.004% eye drops, 1 drop nightly for 3 months
3
latanoprost 0.005%
latanoprost 0.005% eye drops
latanoprost 0.005%, 1 drop nightly for 3 months
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Bimatoprost 0.03%
bimatoprost 0.03%, 1 drop nightly for 3 months
travoprost 0.004%
travoprost 0.004% eye drops, 1 drop nightly for 3 months
latanoprost 0.005% eye drops
latanoprost 0.005%, 1 drop nightly for 3 months
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Uncontrolled systemic disease
* Active ocular disease other than glaucoma or ocular hypertension
* Pregnant or lactating women or women of childbearing potential NOT utilizing a medically acceptable form of birth control
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Allergan
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director
Role: STUDY_DIRECTOR
Allergan
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
San Diego, California, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Whitson JT, Trattler WB, Matossian C, Williams J, Hollander DA. Ocular surface tolerability of prostaglandin analogs in patients with glaucoma or ocular hypertension. J Ocul Pharmacol Ther. 2010 Jun;26(3):287-92. doi: 10.1089/jop.2009.0134.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MA-LUM-07-003
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.